about
Neoantigen-based cancer immunotherapyImmunotherapy in pancreatic cancer: Unleash its potential through novel combinations.CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.Recent advances in immuno-oncology and its application to urological cancers.Precision medicine, genomics and drug discovery.Unleashing the immune response against childhood solid cancers.Implementing liquid biopsies into clinical decision making for cancer immunotherapy.BTLA identifies dysfunctional PD-1-expressing CD4+ T cells in human hepatocellular carcinoma.Immune monitoring technology primer: whole exome sequencing for neoantigen discovery and precision oncology.Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors.The dawn of "immune-revolution" in children: early experiences with checkpoint inhibitors in childhood malignancies.Acquired resistance to immunotherapy and future challenges.Preclinical and clinical development of neoantigen vaccines.Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma.Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response
P2860
Q26738693-90851F32-A94C-4E92-97CA-D6F64AD01220Q33779875-500C70ED-21A0-4CDE-B886-725DD6C87DBEQ37029731-37F0B875-60AC-4B51-A996-0F100CC0E0C0Q37474092-F87ECDDF-8D93-4C82-BD6A-28F2F6223D49Q38377528-636365FD-6805-4ADC-9BAA-D0F7F4185C08Q38819745-A0DC980A-25CC-418A-BEDE-69F1D6FAA0CEQ38931024-AFE568CF-65E7-40AD-B007-0F7170E44B1FQ39224315-941F1053-A019-45DE-BA77-D20725EB215BQ39304648-E69B76FD-9E18-4DE0-9C85-0D39CE0785ABQ40357836-08690CEE-AB84-4EF0-8354-A537445B5B63Q47101602-E2308FB9-0C78-4E0F-8DC5-95A7D49E749DQ47712161-36C8F0EC-6F63-49AD-8BA1-45D15AB45D58Q47724505-A2B3CD13-A680-4C64-83DA-B27E206A063AQ48235785-86222516-DF82-45A5-9049-8F2022848584Q49668436-9C3E3C32-FC16-4395-9756-54A823BDD220Q50080885-E84AEE3C-801E-4B47-8551-482774E642C7Q59133970-DF2BAF19-9BD7-430E-BFEC-F26C9829DCA9
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
CANCER. The odds of immunotherapy success
@ast
CANCER. The odds of immunotherapy success
@en
CANCER. The odds of immunotherapy success
@nl
type
label
CANCER. The odds of immunotherapy success
@ast
CANCER. The odds of immunotherapy success
@en
CANCER. The odds of immunotherapy success
@nl
prefLabel
CANCER. The odds of immunotherapy success
@ast
CANCER. The odds of immunotherapy success
@en
CANCER. The odds of immunotherapy success
@nl
P2860
P356
P1433
P1476
CANCER. The odds of immunotherapy success
@en
P2093
Matthew M Gubin
Robert D Schreiber
P2860
P356
10.1126/SCIENCE.AAD4140
P407
P577
2015-10-09T00:00:00Z